Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
AstraZeneca
Merck
Moodys
Colorcon

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR OLANZAPINE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Olanzapine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000373 ↗ Treatment of Obsessive-Compulsive Disorder Completed National Institute of Mental Health (NIMH) Phase 4 1992-09-01 The purpose of this study is to find the best treatment for Tourette's Syndrome (TS)-spectrum obsessive-compulsive disorder (OCD), which includes symptoms of TS, e.g., repeated and involuntary body movements (tics). There are 2 parts to this study: In Part 1, patients are placed into 1 of 2 groups based on type of OCD, determined by medical history and family member interviews. In Part 2, patients are treated with fluvoxamine (FVX) for 8 weeks. If patients do not respond to FVX alone, either haloperidol or an inactive placebo will be added to the FVX regimen; patients will take this drug combination for 4 weeks. Patients will be monitored throughout the trial.
NCT00000373 ↗ Treatment of Obsessive-Compulsive Disorder Completed University of Florida Phase 4 1992-09-01 The purpose of this study is to find the best treatment for Tourette's Syndrome (TS)-spectrum obsessive-compulsive disorder (OCD), which includes symptoms of TS, e.g., repeated and involuntary body movements (tics). There are 2 parts to this study: In Part 1, patients are placed into 1 of 2 groups based on type of OCD, determined by medical history and family member interviews. In Part 2, patients are treated with fluvoxamine (FVX) for 8 weeks. If patients do not respond to FVX alone, either haloperidol or an inactive placebo will be added to the FVX regimen; patients will take this drug combination for 4 weeks. Patients will be monitored throughout the trial.
NCT00000374 ↗ Treatment for First-Episode Schizophrenia Completed National Institute of Mental Health (NIMH) Phase 4 1998-09-01 This 3-year study will determine if the antipsychotic medications olanzapine (Zyprexa®) and risperidone (Risperdal®) can help patients with first-episode schizophrenia.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Olanzapine

Condition Name

Condition Name for Olanzapine
Intervention Trials
Schizophrenia 234
Bipolar Disorder 55
Schizoaffective Disorder 54
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Olanzapine
Intervention Trials
Schizophrenia 249
Psychotic Disorders 90
Disease 83
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Olanzapine

Trials by Country

Trials by Country for Olanzapine
Location Trials
Canada 73
China 47
Germany 43
Spain 39
India 35
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Olanzapine
Location Trials
New York 83
California 78
Texas 63
Ohio 57
Illinois 53
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Olanzapine

Clinical Trial Phase

Clinical Trial Phase for Olanzapine
Clinical Trial Phase Trials
Phase 4 161
Phase 3 125
Phase 2/Phase 3 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Olanzapine
Clinical Trial Phase Trials
Completed 348
Terminated 39
Recruiting 31
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Olanzapine

Sponsor Name

Sponsor Name for Olanzapine
Sponsor Trials
Eli Lilly and Company 86
National Institute of Mental Health (NIMH) 33
Merck Sharp & Dohme Corp. 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Olanzapine
Sponsor Trials
Other 459
Industry 272
NIH 52
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Colorcon
AstraZeneca
Baxter
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.